Spinal Muscle Atrophy

1. What is it? Any common name for this procedure?

Spinal Muscular Atrophy (SMA) is a rare, genetic neuromuscular disorder that causes muscles to become weak and waste away (atrophy). It occurs when there is a loss of specialized nerve cells in the spinal cord, called motor neurons, which control voluntary muscle movement. Without these signals from the brain, muscles cannot function and eventually shrink.

SMA is caused by a deficiency in a protein called SMN (survival motor neuron), typically due to a mutation in the SMN1 gene. It is a progressive condition, but recent breakthroughs in gene therapy have significantly changed the outlook for patients.

Common Names / Types:

• Type 0: Prenatal onset (rare and most severe).
• Type 1 (Werdnig-Hoffmann Disease): Infantile onset; children usually cannot sit without support.
• Type 2 (Dubowitz Disease): Onset between 6–18 months; children can sit but usually cannot stand or walk independently.
• Type 3 (Kugelberg-Welander Disease): Onset after 18 months; individuals can walk but may lose the ability later in life.
• Type 4: Adult-onset; symptoms are typically mild.

2. Common Symptoms: When to Meet a Doctor

Symptoms vary by type but generally involve "floppiness" and weakness. You should consult a pediatric neurologist if you notice:

• "Floppy" Baby Syndrome: Poor head control or limbs that seem limp (hypotonia).
• Developmental Delays: Failure to reach milestones like sitting up, rolling, or pulling to stand.
• Breathing Difficulties: A bell-shaped chest (where the chest is narrow and the belly moves significantly during breathing).
• Feeding Issues: Difficulty sucking or swallowing (dysphagia), which can lead to choking or poor weight gain.
• Tremors: Fine shaking or quivering in the tongue (fasciculations) or fingers.
• Loss of Motor Skills: An older child who suddenly starts tripping, falling, or has trouble climbing stairs.

3. List of Associated Conditions

Because SMA affects the muscles that support the skeleton and breathing, several complications can arise:

• Scoliosis: A sideways curvature of the spine due to weak back muscles.
• Respiratory Failure: Weakness of the intercostal muscles (between the ribs) makes it hard to cough or breathe deeply, leading to frequent pneumonia.
• Joint Contractures: Permanent tightening of muscles and tendons that restrict joint movement.
• Sleep Apnea: Difficulty breathing during sleep.
• Nutritional Deficiencies: Due to swallowing difficulties or the high metabolic demand of struggling to breathe.

4. List of Screening and Diagnostic Tests

Early diagnosis is critical because "Time is Motoneuron"—once motor neurons are lost, they cannot be recovered.

• Newborn Screening (NBS): In many regions, babies are tested at birth via a heel-prick blood test to identify SMN1 deletions before symptoms appear.
• Genetic Testing: The gold standard; a blood test to look for deletions or mutations in the SMN1 and SMN2 genes.
• Electromyography (EMG): Measures the electrical activity of muscles to see if they are receiving signals from nerves.
• Nerve Conduction Velocity (NCV): Measures how fast signals travel through the nerves.
• Muscle Biopsy: Rarely used today but may be performed to rule out other muscular dystrophies.

5. Am I Eligible for Treatment?

Eligibility for modern disease-modifying therapies is very specific:

1. Genetic Confirmation: You must have a laboratory-confirmed mutation in the SMN1 gene.
2. Age/Weight (for Gene Therapy): Zolgensma (gene replacement) is typically for children under age 2.
3. Symptom Status: Treatment is most effective when started pre-symptomatically (after a positive newborn screen but before weakness begins).
4. Clinical Stability: Patients must be stable enough to undergo the administration (e.g., no active severe infections).

6. Pre and Post Care / Management

Pre-Care (Before Treatment):

• Liver Function Tests: Required before gene therapy, as the treatment can impact the liver.
• Steroid Pre-treatment: Often prescribed to prevent the immune system from reacting to the viral vector used in gene therapy.

Post-Care (Long-term Management):

• Physical & Occupational Therapy: Crucial to help the child gain strength and learn how to use their muscles as they grow.
• Pulmonary Support: Use of "Cough Assist" machines or BiPAP to help with breathing.
• Nutritional Support: Feeding tubes (G-tubes) may be necessary if swallowing becomes unsafe.
• Orthopedic Care: Bracing or surgery to manage scoliosis or hip displacement.

7. Days Required for Hospitalization

• Diagnosis: 0 days (Outpatient blood draw).
• Gene Therapy Infusion: Usually a 1-day outpatient visit or a short observation stay.
• Nusinersen (Spinraza) Injections: A procedure in the hospital (lumbar puncture) taking 2–4 hours, performed every 4 months.
• Scoliosis Surgery: 5 to 7 days in the hospital.

Disclaimer: As per doctor’s advise the number of day’s may get modified based on the specific treatment chosen, the patient's age, and how well they tolerate the medication.

8. Benefits of Management

• Survival: Modern treatments have dramatically increased life expectancy, especially for Type 1 infants who previously rarely lived past age 2.
• Motor Milestone Achievement: Many children treated early are now hitting milestones like sitting, standing, and even walking.
• Reduced Hospitalizations: Better respiratory management means fewer emergency visits for pneumonia.
• Improved Quality of Life: Technology and therapy allow individuals with SMA to attend school, use power wheelchairs, and lead fulfilling, independent lives.